Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy

Journal of Hepatology

Volumn 66, Issue 2, 2017, Pages 464-

  Tsai, Pei Chien ^a   Huang, Chung Feng ^a,b   Yu, Ming Lung ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT; INTERFERON;

ANTIVIRAL THERAPY; CANCER RECURRENCE; CANCER THERAPY; DIRECT ACTING ANTIVIRAL THERAPY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; LIVER CELL CARCINOMA; PRIORITY JOURNAL; HEPACIVIRUS; LIVER TUMOR; TUMOR RECURRENCE;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPACIVIRUS; HUMANS; INTERFERONS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL;

EID: 85007256321     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.10.035     Document Type: Letter

References (3)

1. [1] Reig, M., Marino, Z., Perello, C., Inarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65 (2016), 719–726.
2. [2] Huang, J.F., Yeh, M.L., Yu, M.L., Dai, C.Y., Huang, C.F., Huang, C.I., et al. The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients. J Gastroenterol Hepatol 30 (2015), 1768–1774.
3. [3] Nault, J.C., Colombo, M., Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol 65 (2016), 663–665.